



US006337324B1

(12) **United States Patent**  
**Harmenberg et al.**

(10) **Patent No.:** **US 6,337,324 B1**  
**(45) Date of Patent:** **\*Jan. 8, 2002**

(54) **PHARMACEUTICAL COMBINATION**

(75) **Inventors:** **Johan Georg Harmenberg**, Stockholm;  
**Ann Harriet Margareta Kristofferson**,  
Södertälje, both of (SE)

(73) **Assignee:** **Medivir, AB**, Huddinge (SE)

(\*) **Notice:** This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) **Appl. No.:** **08/612,847**

(22) **PCT Filed:** **Feb. 2, 1996**

(86) **PCT No.:** **PCT/SE96/00124**

§ 371 Date: **Mär. 8, 1996**

§ 102(e) Date: **Mar. 8, 1996**

(87) **PCT Pub. No.:** **WO96/24355**

**PCT Pub. Date:** **Aug. 15, 1996**

(30) **Foreign Application Priority Data**

Feb. 6, 1995 (WO) ..... PCT/SE95/00114

(51) **Int. Cl.<sup>7</sup>** ..... **A61K 31/56**

(52) **U.S. Cl.** ..... **514/171; 514/75; 514/81;**  
**514/82; 514/85; 514/120; 514/179**

(58) **Field of Search** ..... **514/179, 171,**  
**514/75; 518/85, 81, 82, 120**

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

3,317,384 A 5/1967 Underwood ..... 167/58  
4,512,978 A 4/1985 Inwood ..... 424/145  
4,610,868 A 9/1986 Fountain et al. .... 424/1.1  
6,068,860 A \* 5/2000 Carlsson et al. .... 424/601

**FOREIGN PATENT DOCUMENTS**

AU 0636255 \* 5/1992 ..... A61K/31/66  
AU 636255 4/1993 ..... A61K/31/66  
EP 0350287 1/1990 ..... A61K/31/70  
EP 0594223 4/1994 ..... A61K/31/70  
WO 9219244 11/1992 ..... A61K/31/57  
WO 9503805 2/1995 ..... A61K/31/52  
WO 9527501 10/1995 ..... A61K/38/21

**OTHER PUBLICATIONS**

Alenius, S., et al; Therapeutic Effects of Foscarnet Sodium and Acyclovir on Cutaneous Infections due to Herpes Simplex Virus Type 1 in Guinea Pigs, *J. Inf. Dis.* 1982; 145:569-73.

The Human Herpesviruses, ed. Roizman et al. 1993, Whitely, Richard et al.; The epidemiology and Clinical Manifestations of Herpes Simplex Virus Infections.

Kristofferson, A. et al.; Limited Efficacy of Inhibitors of Herpes Simplex Virus DNA Synthesis in Murine Models of Recrudescence Disease, *J. Gen. Virol.* (1988), 69, 1157-1166.

Schinazi, R.F. et al; Studies In Vitro and In Vivo of Combinations of Antivirals and Antiinflammatory Agents in Relation to the Treatment of Herpes Simplex Viruses, Current Chemotherapy and Immunotherapy, 12th Int. Congress, Florence, Jul. 1981.

From Chemical Abstracts, vol. 112, nr. CA:125021: Loftson, T.; Effect of choline esters and oleic acid on the penetration of acyclovir, estradiol, hydrocortisone, nitroglycerin, retinoic acid and trifluorothymidine across hairless mouse skin in vitro, *Acta Pharm. Nor.* (1989), 1(5), 279-86.

From Chemical Abstracts, vol. 112, nr 4, (dissertation): Choi, Hoo Kyun: Enhanced transdermal delivery of propanolol, hydrocortisone, acyclovir and peptide-type drugs (1989).

Power, W J et al., Acyclovir ointment plus topical betamethasone or placebo in first episode disciform keratitis, *British Journal of Ophthalmology* 1992; 76:711-713.

McGill, J. Herpes zoster ocular infection, *Scand. J. Infect. Dis. Suppl.* 46: 85-88, 1985.

ABPI Compendium of Data Sheets and Summaries of Product Characteristics, 1996-97, Datapharm Publications Ltd., pp. 390 and 1271.

Berkow, et al., The Merck Manual of Diagnosis and Therapy, 14<sup>th</sup> Edition, pp. 2023-2025 (1982).

Chemical Abstract No. 97: 156002r from Schinazi, et al., *Curr. Chemother. Immunother.* 2, 1085-1087 (1982).\*

Merck Index 10th Ed #140, #4135, #1435, 1984.\*

Notter et al, 89 CA:157769t, 1978.\*#jfl39##

*Primary Examiner*—Frederick Krass

(74) *Attorney, Agent, or Firm*—White & Case LLP

(57) **ABSTRACT**

The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the prophylactic and curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of a combination of a topically acceptable antiviral substance and an antiinflammatory glucocorticoid for the manufacture of a medicament for said prophylactic and curative treatment.